

# Composite Comorbidity Scoring System to Predict Mortality in a Saudi Dialysis **Population.**

Ezzedine Abderrahim, Ayman S. Moussa, Afef Dridi, Ibrahim A. Jubran, Saad S. Alobaili, Salwa I. Alahmadi, Wisam H. A. Al-Badr

DaVita, Saudi Arabia

## Introduction

- The use of common comorbidity indices and more specific scores were proposed as predisposing factor of the outcome in dialysis population but did not unanimously applied to summarize comorbid status.
- Few studies described the development and the validation of adapted scores as predictors of both morbidity and mortality in such patients. Establishment of such scores should aim to guide clinicians towards patients' personalized interventional care.


### Objective

- Our aim was to establish and evaluate a personal scoring system where we included associated comorbidities and other factors known to predict mortality in HD patients.
- Identification of high risk groups can guide medical teams to implement specific preventive measures on the aim to reduce fatal events.

### Methods (1)

- We included all patients referred to DaVita-KSA clinics to continue renal replacement with HD from October 2014 to December 2019.
- Baseline data, including demographics and clinical characteristics recorded at admission, were compiled from monthly reports elaborated by DaVita-KSA clinics as well as the main events occurring during the followup period.
- Patient survival was analysed from the date of starting dialysis in DaVita-KSA clinics to endpoint corresponding to kidney transplantation, or patient transfer to another dialysis facility, or death, or December 31, 2019 (end of the study).
- Cox proportional hazards model was used to identify factors influencing mortality. Among 25 potential parameters (Table 1A), we identified 18 predictors of death in the preliminary univariate analysis (Table 1B). A personal scoring system was established (Table 1C) on the basis of the score assigned to each factor according to its weight as death predictor judged on the value of the relative risk generated by the preliminary analysis (Table 1D). An index of co-morbidity was calculated for each patient that corresponded to the sum of scores assigned to each factor.
- Included patients were divided into 4 groups according to percentile rank of their final comorbidity index (Group1: low risk, Group 2: moderate, Group 3: high, Group 4: very high). These groups were compared in terms of global and annual mortality rates and survival using Log rank analysis. The level of statistical significance was set at 5%.

Chror Calciu Phosp Calciu Parath




# Methods (2)

Table 1: List of tested parameters and their weight in the scoring system

		0		0 /			rable 2. Plottanty pe							
able 1A: Parameters	Table 1B:			Parameter	Variable	Score	Groups		Total	Group 1	Group 2	Group 3	Group 4	
ender	Parameter	Variable	Score	10 Dementia	Yes	3	Number		3983	882	867	1237	997	
e	HD duration	< 3 months	1	10 Dementia	No	0	Comorbidity Score		[0-22]	[0-3]	[4-5]	[6-8]	≥ 9	
Oduration before Joining DaVita	1 before Joining DaVita	>= 3 months	0	11 Smoking	Yes	1		Rate [CI,95%]	14.5 [13.3-				00 4 [00 00 7]	
scular Access			0		No	0	Mortality*, %		15.7]	3.6 [2.4-4.9]	8.4 [6.5-10.3]	14.5 [12.3-16.6]	29.4 [26-32.7]	
ody mass index (BMI)		< 50 years	0	12 Stroke-Immobile- Amputation	Yes	2	Annual Mortality*, %	Rate [CI, 95%]	7.6 [6.9-8.2]	1.5 [1-2]	4.3 [3.3-5.2]	8.2 [7-9.4]	18.1 [16.1-20.2]	
pertension (HTN)		50-60 years	1		No	0								
abetes	2 Age	60-70 years	2	13 Malignancy	Yes	1		3	98.2	99.9	99.3	98.7	95.0	
ngestive heart failure (CHF)	1	70-80 years	3		No Catheter-	0	Survival Rate*,	12	94.0	98.8	97.6	94.1	86.2	
oronary artery disease (CAD)		> 80 years	4	14 Vascular Access	Catheter	2		24	86.7	96.9	93.2	86.6	71.0	
ripheral vascular disease (PVD)		Under weight & Normal	1		Other	0		60	65.3	92.6	68.8	59.0	37.2	
rhythmia	3 BMI	-	-		< 10	1		00	00.0	52.0	00.0	00.0	57.2	
ementia		Obese & over weight Yes	0	15 Hemoglobin	>=10	0	<b>RR for Mortality *</b>	Rate [CI, 95%]		1 [Reference]	2.9 [1.9-4.4]	5.7 [3.9-8.3]	12.9 [8.9-18.5]	
ronic obstructive pulmonary sease (COPD)	4 HTN	No	1	16 Transferrin saturation	< 20	1								
roke-Immobile-Amputation			-	10 mansientin saturation	>= 20	0	Comments & Conclusions							
ver-Virology	5 Diabetes	Yes	Z	17 Ferritin	< 800	0								
alignancy		No	0		>= 800	1	<ul> <li>Patients on maintenance</li> </ul>	e HD are at increased	d risk of mortality.	Most of them sta	rted HD with mult	iple comorbidities ar	nd have numerous	
a of GIT bleeding	6 CHF	Yes	2	18 Albumin	<= 35	1	risk factors exposing them to cardiovascular complications. Other specific conditions make these patients very vulnerable.							
emoglobin		No	0		> 35	0	<ul> <li>Few studies described</li> </ul>	the development and	d the validation o	of adapted scores	as predictors of	both morbidity and	mortality in such	
ansferrin saturation	7 CAD	Yes	2	Total Score		0 - 28	patients. Establishment of such scores should aim to guide clinicians towards patients' personalized interventional care.							
rritin	7 CAD	No	0	Table 1C:			<ul> <li>Few published studies f</li> </ul>		-	•	•			
lcium		Yes	1				·						•	
osphorus	8 PVD	No	0	Relative Risk	Weight sc	ore	might influence the outo	-						
lcium-phosphorus product		Yes	1	[1-2[	1		• The scoring system we		-	aking into accoun	t in addition to c	ommon comorbiditie	es, age and, other	
rathyroid hormone (PTH)	9 Arrhythmia	No	0	[2-3[	2		specific parameters rela	ted to dialysis treatm	ent.					
			0	>=3	5	• Our results demonstrated its relevance as a good predictor for mortality in our HD population but it need an external validation since by								

# Results (1)



DIALYSIS Duration, Months								
24	36	48	60					
96.9	95.4	93.2	92.6					
93.2	88.5	85	68.8					
86.6	78	66	59					
71	55.6	46	37.2					

# Results (2)

### Table 2: Mortality parameters in 4 groups categorized according to their comorbidity score

- HD patients with high comorbidity index are excluded to be treated in outpatient facilities.

### References

1- De Jager DJ, Grootendorst DC, Jager KJ et al. Cardiovasular and non cardiovascular mortality among patients starting dialysis. JAMA 2009; 302: 1782–1789. 2- US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States. Chapter 5: Mortality. Am J Kidney Dis 2019; 73(3), Supplement 1: S412-S426. 3- Kalbfleisch J, Wolfe R, Bell S, Sun R, et al. Risk Adjustment and the Assessment of Disparities in Dialysis Mortality Outcomes. J Am Soc Nephrol. 2015;26(11):2641-5. 4-Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5): 373–83. 5-Beddhu, S., Bruns, F. J., Saul, M., Seddon & Zeidel, M. L. A Simple Comorbidity Scale Predicts Clinical Outcomes and Costs in Dialysis Patients. Am J Medicine 2000; 108: 609–613. 6-Hemmelgarn, B. R., Manns, B. J., Quan, H. & Ghali, W. A. Adapting the Charlson Comorbidity Index for Use in Patients With ESRD. Am J Kidney Dis. 2003; 42(1): 125–132. 7-Floege, J. et al. Development and validation of a predictive mortality risk score from a European hemodialysis cohort. Kidney Int. 2015; 10: 1–13. 8-Liu, J., Huang, Z., Gilbertson, D. T., Foley, R. N. & Collins, A. J. An improved comorbidity index for outcome analyses among dialysis patients. Kidney Int. 2010; 77: 141–151. 9-Couchoud, C. et al. A clinical score to predict 6-month prognosis in elderly patients starting dialysis for end-stage renal disease. Nephrol Dial Transplant. 2009; 24: 1553–1561 10-Tamer, M. et al. Predicting Early Death Among Elderly Dialysis Patients: Development and Validation of a Risk Score to Assist Shared Decision Making for Dialysis Initiation. Am J Kidney Dis. 2015; 66(6): 1024–1032. , Vela, E. & Clèries, M. Development of a predictive model for early death in diabetic patients entering hemodialysis: a population-based study. Acta Diabetol 2008; 45: 203–209. 12-McArthur, E. et al. Comparing Five Comorbidity Indices to Predict Mortality in Chronic Kidney Disease: A Retrospective Cohort Study. Canadian J Kidney Health Dis Disease. 2018; 5: 1–10. 13-SCOT Data Dialysis in the Kingdom of Saudi Arabia. Saudi J Kidney Dis Transpl 2018;29(4):1012-1020 14-AI Wakeel JS, Mitwalli AH, Al Mohaya S, Abu-Aisha H, Tarif N, Malik GH, Hammad D. Morbidity and mortality in ESRD patients on dialysis. Saudi J Kidney Dis Transpl. 2002;13(4):473-7

cknowledgments: The authors thank Drs. Maciej Drozdz & Stefan Jacobson for their kind abstract review. dence : Ayman.Moussa@davita.com/ezzedine.abderrahim@gmail.com

results demonstrated its relevance as a good predictor for mortality in our HD population but it need an external validation since by